PA
CDNA icon

PharVision Advisers’s CareDx CDNA Stock Holding History

PharVision Advisers’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,453
Closed -$348K – 196
2025
Q4 		$348K Buy
+18,453
New +$309K 0.18% 198

Other funds holding CDNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

PharVision Advisers's CDNA Position: Q1 2026 in Review

PharVision Advisers sold out of CareDx (CDNA) in Q1 2026, closing a stake of 18,453 shares — an estimated $348K sold.

PharVision Advisers first reported a position in CDNA in Q4 2025 and held it in 1 quarter. The position peaked at $348K in Q4 2025. 191 funds tracked by Wall St. Rank hold CDNA as of Q1 2026.

  • PharVision Advisers reported no remaining CareDx position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 18,453 CareDx shares in Q1 2026, an estimated $348K.
  • PharVision Advisers first reported a position in CareDx in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's CareDx position peaked at $348K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held CareDx as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.